BerGenBio receives positive recommendation from independent Data and Safety Monitoring Board to proceed without study modification BERGEN, Norway, March 20, 2024 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase…
BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation
This post was originally published on this site